At the completion of the complaint investigation, based on the information received, the clinical evaluation was able to confirm a stent migration, and a total stent collapse that was non-flow limiting.There was also enough evidence to support the following observations; a type 2 endoleak and a type 3b endoleak near the total stent collapse.The clinical evaluation additionally found the following potential contributing factors to the reported event; off label use due to patient anatomy, patent lumbar arteries, patent inferior mesenteric artery, a total stent collapse, and calcification in the left aortic wall.The review of the manufacturing lot confirmed all devices met specifications prior to release.The root cause of the stent collapse and type 2 endoleak is unknown.There is not enough information to determine the cause of the collapsed stent and type 2 endoleak.A root cause investigation was carried out for all afx complaints having an identified failure mode of a type 3b endoleak.Endologix implemented the following corrective actions with the intent of reducing type 3b endoleak events; 1.Upgraded graft material (i.E.Duraply) and 2.Updates to the ifu and additional physician training.The change to duraply graft material and the ifu changes were put in place july 2014.The type 3b endoleak rate for afx manufactured and implanted before these corrective actions were put in place is trending at 2.5%.Since the corrective actions were implemented, the type 3b endoleak events reported for afx devices has been reduced to <0.2%.Correction: device codes have been updated.
|